The role of Bcl-xL in synergistic induction of apoptosis by mapatumumab and oxaliplatin in combination with hyperthermia on human colon cancer

Molecular Cancer Research

Volumn 10, Issue 12, 2012, Pages 1567-1579

  Song, Xinxin ^a   Kim, Seog Young ^a   Lee, Yong J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME C; MAPATUMUMAB; OXALIPLATIN; PROTEIN BAX; PROTEIN BCL XL; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CELL PROLIFERATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; HYPERTHERMIC THERAPY; IN VITRO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MOUSE; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; CYTOCHROMES C; DRUG SYNERGISM; HCT116 CELLS; HUMANS; HYPERTHERMIA, INDUCED; MALE; MAP KINASE KINASE 4; MICE; MICE, NUDE; MITOCHONDRIA; ORGANOPLATINUM COMPOUNDS; PHOSPHORYLATION; PROTEIN TRANSPORT; REACTIVE OXYGEN SPECIES;

EID: 84871381642     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-12-0209-T     Document Type: Article

References (26)

1. Koschny R, Ganten TM, Sykora J, Haas TL, Sprick MR, Kolb A, et al. TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology 2007;45:649-58. (Pubitemid 46450616)
2. Maddipatla S, Hernandez-Ilizaliturri FJ, Knight J, Czuczman MS. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20. Clin Cancer Res 2007;13:4556-64. (Pubitemid 47219726)
3. Pukac L, Kanakaraj P, Humphreys R, Alderson R, Bloom M, Sung C, et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 2005;92:1430-41. (Pubitemid 40705010)
4. Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000;12:599-609.
5. Basu A, Castle VP, Bouziane M, Bhalla K, Haldar S. Crosstalk between extrinsic and intrinsic cell death pathways in pancreatic cancer: synergistic action of estrogen metabolite and ligands of death receptor family. Cancer Res 2006;66:4309-18.
6. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005;12:228-37. (Pubitemid 40315182)
7. Song X, Kim HC, Kim SY, Basse P, Park BH, Lee BC, et al. Hyperthermia-enhanced TRAIL- and mapatumumab-induced apoptotic death is mediated through mitochondria in human colon cancer cells. J Cell Biochem 2012;113:1547-58.
8. Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 2002;1:227-35.
9. Upreti M, Galitovskaya EN, Chu R, Tackett AJ, Terrano DT, Granell S, et al. Identification of the major phosphorylation site in Bcl-xL induced by microtubule inhibitors and analysis of its functional significance. J Biol Chem 2008;283:35517-25.
10. Wang J, Beauchemin M, Bertrand R. Phospho-Bcl-xL(Ser62) plays a key role at DNA damage-induced G 2 checkpoint. Cell Cycle 2012;11:2159-69.
11. Zhai D, Jin C, Satterthwait AC, Reed JC. Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ 2006;13:1419-21. (Pubitemid 44057478)
12. Yu J, Zhang L. PUMA, a potent killer with or without p53. Oncogene 2008;27(Suppl 1):S71-83.
13. Trarbach T, Moehler M, Heinemann V, Kohne CH, Przyborek M, Schulz C, et al. Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br J Cancer 2010;102:506-12.
14. Belyanskaya LL, Marti TM, Hopkins-Donaldson S, Kurtz S, Felley-Bosco E, Stahel RA. Human agonistic TRAIL receptor antibodies mapatumumab and lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin. Mol Cancer 2007;6:66.
15. Fan QL, Zou WY, Song LH, Wei W. Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo. Cancer Chemother Pharmacol 2005;55:189-96. (Pubitemid 40110062)
16. Hegewisch-Becker S, Gruber Y, Corovic A, Pichlmeier U, Atanackovic D, Nierhaus A, et al. Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study. Ann Oncol 2002;13:1197-204. (Pubitemid 34960127)
17. Venkataraman S, Wagner BA, Jiang X, Wang HP, Schafer FQ, Ritchie JM, et al. Overexpression of manganese superoxide dismutase promotes the survival of prostate cancer cells exposed to hyperthermia. Free Radic Res 2004;38:1119-32. (Pubitemid 39504348)
18. Gamaley IA, Klyubin IV. Roles of reactive oxygen species: signaling and regulation of cellular functions. Int Rev Cytol 1999;188:203-55. (Pubitemid 129751068)
19. Choi K, Ryu SW, Song S, Choi H, Kang SW, Choi C. Caspase-dependent generation of reactive oxygen species in human astrocytoma cells contributes to resistance to TRAIL-mediated apoptosis. Cell Death Differ 2010;17:833-45.
20. Song JJ, Lee YJ. Differential role of glutaredoxin and thioredoxin in metabolic oxidative stress-induced activation of apoptosis signal-regulating kinase 1. Biochem J 2003;373:845-53. (Pubitemid 36981094)
21. Song JJ, Lee YJ. Catalase, but not MnSOD, inhibits glucose deprivation-activated ASK1-MEK-MAPK signal transduction pathway and prevents relocalization of Daxx: hydrogen peroxide as a major second messenger of metabolic oxidative stress. J Cell Biochem 2003;90:304-14. (Pubitemid 37222199)
22. Ubersax JA, Ferrell JE Jr. Mechanisms of specificity in protein phosphorylation. Nat Rev Mol Cell Biol 2007;8:530-41. (Pubitemid 46985383)
23. Basu A, Haldar S. Identification of a novel Bcl-xL phosphorylation site regulating the sensitivity of taxol- or 2-methoxyestradiol-induced apoptosis. FEBS Lett 2003;538:41-7. (Pubitemid 36287422)
24. Kharbanda S, Saxena S, Yoshida K, Pandey P, Kaneki M, Wang Q, et al. Translocation of SAPK/JNK to mitochondria and interaction with Bcl-x(L) in response to DNA damage. J Biol Chem 2000;275:322-7. (Pubitemid 30038988)
25. Edlich F, Banerjee S, Suzuki M, Cleland MM, Arnoult D, Wang C, et al. Bcl-x(L) retrotranslocates Bax from the mitochondria into the cytosol. Cell 2011;145:104-16.
26. Younes A, Vose JM, Zelenetz AD, Smith MR, Burris HA, Ansell SM, et al. A phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma. Br J Cancer 2010;103:1783-7.